23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Iovance Biotherapeutics, Inc. › 2025-2026

Iovance Biotherapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Iovance Biotherapeutics, Inc.’s Form 8-K, filed June 10, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 13Reported items
  • 225Asset managers, any item
  • 2,647Fund votes
  • June 10, 2026Meeting date

Results at a glance

Meeting of June 10, 2026: 11 items on Iovance Biotherapeutics, Inc.’s Form 8-K, filed June 10, 2026: 5 approved · 6 passed (calculated).

Dissent

Notable dissent: 3 other board items (21.9%, 18.4%, 17.4% against).

  • This proposal was approved with 254,976,692 "FOR" votes, 71,438,492 "AGAINST" votes and 3,077,496 "ABSTAIN" votes 78% of votes cast Approved Notable · 21.9% against
  • This proposal was approved with 160,497,888 "FOR" votes, 36,117,764 "AGAINST" votes and 2,697,741 "ABSTAIN" votes 82% of votes cast Approved Notable · 18.4% against
  • This proposal was approved with 267,867,310 "FOR" votes, 56,350,642 "AGAINST" votes and 5,274,728 "ABSTAIN" votes 83% of votes cast Approved Notable · 17.4% against

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Iovance Biotherapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Iovance Biotherapeutics, Inc.

These tallies are Iovance Biotherapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 10, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Iovance Biotherapeutics, Inc. — official shareholder meeting results, meeting held June 10, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Dr. Dukes 182,990,471---- 16,322,922130,179,287 92%Passed (calculated)—
Elect Director: Dr. Countouriotis 186,590,407---- 12,722,986130,179,287 94%Passed (calculated)—
Elect Director: Mr. Maynard 186,379,215---- 12,934,178130,179,287 94%Passed (calculated)—
Elect Director: Mr. Rothbaum 183,881,242---- 15,432,151130,179,287 92%Passed (calculated)—
Elect Director: Dr. Vogt 181,341,958---- 17,971,435130,179,287 91%Passed (calculated)—
Elect Director: Dr. Weiser 185,454,684---- 13,858,709130,179,287 93%Passed (calculated)—
This proposal was approved with 160,497,888 "FOR" votes, 36,117,764 "AGAINST" votes and 2,697,741 "ABSTAIN" votes 160,497,88836,117,7642,697,741 --130,179,287 82%Approved—
This proposal was approved with 317,671,584 "FOR" votes, 6,433,002 "AGAINST" votes and 5,388,094 "ABSTAIN" votes 317,671,5846,433,0025,388,094 --0 98%Approved—
This proposal was approved with 178,677,284 "FOR" votes, 18,961,472 "AGAINST" votes and 1,674,637 "ABSTAIN" votes 178,677,28418,961,4721,674,637 --130,179,287 90%Approved—
This proposal was approved with 254,976,692 "FOR" votes, 71,438,492 "AGAINST" votes and 3,077,496 "ABSTAIN" votes 254,976,69271,438,4923,077,496 --0 78%Approved—
This proposal was approved with 267,867,310 "FOR" votes, 56,350,642 "AGAINST" votes and 5,274,728 "ABSTAIN" votes 267,867,31056,350,6425,274,728 --0 83%Approved—

This meeting is also recorded here as June 4, 2026; both records come from the same filing, so the date should be checked against it.

Source: Iovance Biotherapeutics, Inc., Form 8-K, filed with the SEC on June 10, 2026 — read the filing on EDGAR.

How asset managers voted at the Iovance Biotherapeutics, Inc. 2025-2026 meeting

225 asset managers disclosed a vote on at least one Iovance Biotherapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Iovance Biotherapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Dr. Countouriotis

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 186,590,407WITHHELD: 12,722,986
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Athena Countouriotis, M.D.

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Countouriotis”): 186,590,407 for, 12,722,986 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 44,873,429 for, 61,735 withheld, 59 abstained.

FOR
FOR: 44,873,429ABSTAIN: 59WITHHOLD: 61,735
Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,898,4480 5930,728For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,195,1380 01,303For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Dr. Vogt

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

91% Majority: yes · of votes cast

FOR 91%
FOR: 181,341,958WITHHELD: 17,971,435
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Frederick G. Vogt, Ph.D., J.D.

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Vogt”): 181,341,958 for, 17,971,435 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 91% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 44,935,143 for, 79 abstained.

FOR
FOR: 44,935,143ABSTAIN: 79
Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,929,1560 790For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,196,4410 00For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Dr. Dukes

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 182,990,471WITHHELD: 16,322,922
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Iain Dukes, D. Phil.

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Dukes”): 182,990,471 for, 16,322,922 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 44,321,910 for, 613,247 withheld, 66 abstained.

FOR
FOR: 44,321,910ABSTAIN: 66WITHHOLD: 613,247
Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,883,5500 6645,619For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,195,1380 01,303For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust00 0536,284Withhold
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Dr. Weiser

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 185,454,684WITHHELD: 13,858,709
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Michael Weiser, M.D., Ph.D.

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Weiser”): 185,454,684 for, 13,858,709 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 44,668,786 for, 266,375 withheld, 62 abstained.

FOR
FOR: 44,668,786ABSTAIN: 62WITHHOLD: 266,375
Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,898,4450 6230,728For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,195,1380 01,303For
Equitable523,5600 0204,640Mixed
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Mr. Maynard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 186,379,215WITHHELD: 12,934,178
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Ryan Maynard

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Maynard”): 186,379,215 for, 12,934,178 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 44,886,217 for, 48,945 withheld, 60 abstained.

FOR
FOR: 44,886,217ABSTAIN: 60WITHHOLD: 48,945
Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,883,5560 6045,619For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,195,1000 01,341For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

Elect Director: Mr. Rothbaum

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

92% Majority: yes · of votes cast

FOR 92%
FOR: 183,881,242WITHHELD: 15,432,151
Details: description as filed, official tally, votes by 52 asset managers

Description as filed by funds: To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Meeting of Stockholders: Wayne P. Rothbaum

Iovance Biotherapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Rothbaum”): 183,881,242 for, 15,432,151 withheld, per its Form 8-K filed June 10, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts using a plurality of the votes cast, the standard stated in the company’s proxy statement: votes for exceeded votes against.
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 52 asset managers below reported 44,901,139 for, 34,016 withheld, 68 abstained.

FOR
FOR: 44,901,139ABSTAIN: 68WITHHOLD: 34,016
Largest asset managers voting on “To elect six directors named in the proxy statement accompanying this notice to serve until the 2027 Annual Me” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,898,4390 6830,728For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,195,1380 01,303For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 52 asset managers. All 52 are in the interactive database (link above).

To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of…

No official matchCAPITAL STRUCTURE

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 53 asset managers

Description as filed by funds: To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized shares of the Company's common stock from 500,000,000 shares to 650,000,000 shares; and

The 53 asset managers below reported 44,935,126 for, 119 against, 8 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 44,935,126AGAINST: 119ABSTAIN: 8
Largest asset managers voting on “To approve an amendment to our Certificate of Incorporation, as amended, to increase the number of authorized ” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,929,107119 80For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,196,4410 00For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not…

93% of fund votes cast · no official result

FOR
Details: description as filed, votes by 53 asset managers

Description as filed by funds: To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Annual Meeting to approve Proposal 6.

The 53 asset managers below reported 41,889,414 for, 3,045,828 against, 10 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 41,889,414AGAINST: 3,045,828ABSTAIN: 10
Largest asset managers voting on “To approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not ” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,929,101122 100For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price01,533,294 00Against
Fidelity1,422,2430 00For
State Street3,7441,192,697 00Against
Equitable687,50940,691 00Mixed
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial41,415204,200 00Mixed
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock87,51059,287 00Mixed
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's…

No official matchCOMPENSATION

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 54 asset managers

Description as filed by funds: To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Company's common stock authorized for issuance thereunder by 1,000,000 shares;

The 54 asset managers below reported 44,943,702 for, 84 against, 8 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 44,943,702AGAINST: 84ABSTAIN: 8
Largest asset managers voting on “To approve an amendment to our 2020 Employee Stock Purchase Plan to increase the number of shares of the Compa” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,929,14484 80For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,196,4410 00For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 54 asset managers. All 54 are in the interactive database (link above).

To approve, by non-binding advisory vote, the compensation of our named executive officers

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 6 wordings of this item as funds reported it.

84% Fund and manager reports combined; may count the same shares twice · no official result

FORAGAINST
Details: description as filed, votes by 223 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the compensation of our named executive officers;

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 52 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,929,067156 120For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price01,533,294 00Against
Fidelity1,422,2430 00For
State Street1,195,2291,212 00For
Equitable482,869245,331 00Mixed
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I0413,436 00Against
American Century0379,377 00Against
AIG/SunAmerica0290,611 00Against
Tema ETF Trust278,2360 00For
ProShares0256,123 00Against
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock0146,797 00Against
SEI132,3900 00For
Dimensional0111,269 00Against
Direxion Shares ETF Trust0110,628 00Against
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds082,893 00Against
Jackson National075,670 00Against

Fund voting reports, all 52 managers: 41,026,856 for, 3,908,355 against, 12 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 187 asset managers voting on “To approve, by non-binding advisory vote, the compensation of our named executive officers;” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
MHR FUND MANAGEMENT LLC29,053,9510 00For
Invenomic Capital Management LP7,849,4530 00For
BlackRock5,900,70341,714 00For
State Street4,649,19159,112 00For
Nuveen3,586,9520 00For
Charles Schwab2,787,8600 00For
Vanguard2,639,66415,210 00For
T. Rowe Price02,457,470 00Against
MARSHALL WACE, LLP2,244,0740 00For
DE Shaw01,901,240 00Against
Two Sigma01,861,218 00Against
Knott David M Jr01,600,000 00Against
Northern Trust1,388,65488,803 00Mixed
WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC1,369,4100 00For
GEODE CAPITAL MANAGEMENT, LLC1,295,8410 00For
C WorldWide Asset Management Fondsmaeglerselskab A/S01,260,000 00Against
RICE HALL JAMES & ASSOCIATES, LLC1,171,8400 00For
Mirador Capital Partners LP00 1,054,0980Abstain
STIFEL NICOLAUS & CO INC \MO\0712,904 00Against
WELLS FARGO CLEARING SERVICES, LLC678,4290 00For
Goldman Sachs661,8650 00For
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND0628,537 00Against
RBC Capital Markets, LLC0600,119 00Against
AQR0493,980 00Against
QVT Financial LP473,3890 00For

Institutional-manager reports, all 187 managers: 67,897,976 for, 16,279,907 against, 1,056,427 abstained, 4,791 not voted, 171,366 1 year. Showing the 25 largest; every one is in the interactive database (link above).

To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

21% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 187 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named executive officers;

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 44 asset managers voting on “To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named e” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard00 190Abstain
BlackRock00 00--
TIAA00 00--
T. Rowe Price00 00--
Fidelity00 00--
State Street00 00--
Equitable00 00--
JPMorgan00 00--
Northern Trust00 00--
ETFis Series Trust I00 00--
American Century00 00--
AIG/SunAmerica00 00--
Tema ETF Trust00 00--
ProShares00 00--
Lincoln Financial00 00--
Bridge Builder Trust00 00--
John Hancock00 00--
Dimensional00 00--
Direxion Shares ETF Trust00 00--
Blackstone Alternative Investment Funds00 00--
Jackson National00 00--
Goldman Sachs00 00--
Pacific Life00 00--
DWS00 00--
SA FUNDS INVESTMENT TRUST00 00--

Fund voting reports, all 44 managers: 40,703 for, 19 abstained, 41,371,186 1 year, 258,959 3 year, 747 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 155 asset managers voting on “To approve, by non-binding advisory vote, the frequency of our future votes on the compensation of our named e” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock00 00--
Palo Alto Investors LP00 00--
State Street00 00--
Nuveen00 00--
Vanguard00 00--
T. Rowe Price00 00--
DE Shaw00 00--
Two Sigma00 00--
Knott David M Jr00 00--
Northern Trust00 00--
WELLS FARGO ADVISORS FINANCIAL NETWORK, LLC00 00--
GEODE CAPITAL MANAGEMENT, LLC00 00--
Mirador Capital Partners LP00 00--
STIFEL NICOLAUS & CO INC \MO\00 00--
WELLS FARGO CLEARING SERVICES, LLC00 00--
Goldman Sachs00 00--
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND00 00--
RBC Capital Markets, LLC00 00--
AQR00 00--
QVT Financial LP00 00--
Dimensional00 00--
MELLON INVESTMENTS Corp00 00--
American Century00 00--
CORSAIR CAPITAL MANAGEMENT, L.P.00 00--
UBS00 00--

Institutional-manager reports, all 155 managers: 4,767 for, 171,366 against, 2,329 abstained, 42,824,447 1 year, 1,553,579 3 year. Showing the 25 largest; every one is in the interactive database (link above).

To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive…

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

— Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: description as filed, votes by 36 asset managers

Description as filed by funds: To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named executive officers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 10 asset managers voting on “To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named execu” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Charles Schwab00 00--
Global X00 00--
SEI00 00--
CLEARWATER INVESTMENT TRUST00 00--
Vanguard00 00--
Venerable Variable Insurance Trust00 00--
Russell Investments00 00--
Nationwide00 00--
NEW COVENANT FUNDS00 00--
Federated Hermes00 00--

Fund voting reports, all 10 managers: 3,263,603 1 year.

Institutional-manager reports: 28 asset managers voting on “To approve, by non-binding advisory vote, the frequency of future votes on the compensation of our named execu” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Invenomic Capital Management LP00 00--
Charles Schwab00 00--
MARSHALL WACE, LLP00 00--
C WorldWide Asset Management Fondsmaeglerselskab A/S00 00--
RICE HALL JAMES & ASSOCIATES, LLC00 00--
Raiffeisen Bank International AG00 00--
SEI00 00--
WASHINGTON STATE INVESTMENT BOARD00 00--
Russell Investments00 00--
BANK OF AMERICA NA00 00--
Arizona State Retirement System00 00--
LOS ANGELES CAPITAL MANAGEMENT LLC00 00--
GRANDFIELD & DODD, LLC00 00--
Neuberger Berman00 00--
Prudential/PGIM00 00--
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM00 00--
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM00 00--
Wealthfront Advisers LLC00 00--
BALYASNY ASSET MANAGEMENT L.P.00 00--
NEW YORK STATE COMMON RETIREMENT FUND00 00--
Universal-Investment-Gesellschaft mbH00 00--
Donor Advised Charitable Giving, Inc.00 00Not Voted
Meeder Advisory Services, Inc.00 00--
YOUSIF CAPITAL MANAGEMENT, LLC00 00--
NISA INVESTMENT ADVISORS, LLC00 00--

Institutional-manager reports, all 28 managers: 4,791 not voted, 16,675,046 1 year. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year…

No official matchAUDIT-RELATED

Combines 3 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FOR
Details: description as filed, votes by 53 asset managers

Description as filed by funds: To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026;

The 53 asset managers below reported 44,935,236 for, 7 against, 10 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 44,935,236AGAINST: 7ABSTAIN: 10
Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for our fi” at Iovance Biotherapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard24,929,2177 100For
BlackRock4,087,8300 00For
TIAA3,555,4260 00For
Charles Schwab2,786,4330 00For
T. Rowe Price1,533,2940 00For
Fidelity1,422,2430 00For
State Street1,196,4410 00For
Equitable728,2000 00For
JPMorgan719,1380 00For
Northern Trust536,2840 00For
ETFis Series Trust I413,4360 00For
American Century379,3770 00For
AIG/SunAmerica290,6110 00For
Tema ETF Trust278,2360 00For
ProShares256,1230 00For
Lincoln Financial245,6150 00For
Global X158,4570 00For
Bridge Builder Trust150,7060 00For
John Hancock146,7970 00For
SEI132,3900 00For
Dimensional111,2690 00For
Direxion Shares ETF Trust110,6280 00For
CLEARWATER INVESTMENT TRUST99,0890 00For
Blackstone Alternative Investment Funds82,8930 00For
Jackson National75,6700 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Largest Iovance Biotherapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 438,106,537 shares outstanding at the time of that meeting.

Fund voting reports: top Iovance Biotherapeutics, Inc. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers;”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 5.69%
2BlackRock 0.93%
3TIAA 0.81%
4Charles Schwab 0.64%
5T. Rowe Price 0.35%
6Fidelity 0.32%
7State Street 0.27%
8Equitable 0.17%
9JPMorgan 0.16%
10Northern Trust 0.12%
Institutional-manager reports: top Iovance Biotherapeutics, Inc. shareholders by shares voted on “To approve, by non-binding advisory vote, the compensation of our named executive officers;”, 2025-2026
#Asset manager % of shares outstanding
1MHR FUND MANAGEMENT LLC 6.63%
2Invenomic Capital Management LP 1.79%
3BlackRock 1.36%
4State Street 1.07%
5Nuveen 0.82%
6Charles Schwab 0.64%
7Vanguard 0.61%
8T. Rowe Price 0.56%
9MARSHALL WACE, LLP 0.51%
10DE Shaw 0.43%

Reported Iovance Biotherapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Iovance Biotherapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
BlackRock, Inc.33,366,587 7.62%Schedule 13G, filed July 28, 2026
New York, NY30,000,000 6.85%Proxy statement (DEF 14A), proxy filed April 28, 2026
Wayne Rothbaum30,000,000 6.85%Proxy statement (DEF 14A), proxy filed April 28, 2026
Malvern, PA25,076,472 5.72%Proxy statement (DEF 14A), proxy filed April 28, 2026
STATE STREET CORPORATION24,478,268 5.59%Schedule 13G, filed August 7, 2026
Frederick G. Vogt, Ph.D., J.D.2,035,731 0.46%Proxy statement (DEF 14A), proxy filed April 28, 2026
Raj K. Puri, M.D., Ph.D.673,225 0.15%Proxy statement (DEF 14A), proxy filed April 28, 2026
Iain Dukes, D. Phil.624,000 0.14%Proxy statement (DEF 14A), proxy filed April 28, 2026
Igor Bilinsky, Ph.D.444,249 0.10%Proxy statement (DEF 14A), proxy filed April 28, 2026
Michael Weiser, M.D., Ph.D.317,632 0.07%Proxy statement (DEF 14A), proxy filed April 28, 2026

Percentages above are of 438,106,537 shares outstanding, as reported by Iovance Biotherapeutics, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Iovance Biotherapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 225 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 2,647 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Iovance Biotherapeutics, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, by non-binding advisory vote, the compensation of our named executive officers; — the reporting funds and managers cast 84% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Iovance Biotherapeutics, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Iovance Biotherapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Iovance Biotherapeutics (IOVA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/iovance-biotherapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.